← Oncology Approval Tracker

FDA DECISION ·

Loqtorzi + cisplatin + gemcitabine

toripalimab-tpzi + cisplatin + gemcitabine · Coherus BioSciences

FDA approvalNew therapyHead and neck cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, with cisplatin and gemcitabine.

LAMPGEN ANALYSIS

Why it matters

This introduced a PD-1 inhibitor plus chemotherapy in a rare head and neck cancer setting.

What research teams should watch

Confirm nasopharyngeal primary site and distinguish first-line use from the separately approved single-agent use.

PRIMARY RECORDS

Sources